索格列净通过延缓肠道葡萄糖吸收降低餐后血糖和胰岛素浓度
一项双盲三周期交叉研究在24名健康人中比较单次索格列净400mg、卡格列净300mg与安慰剂对口服葡萄糖出现率的影响。索格列净和卡格列净均降低早餐及4.25小时午餐后葡萄糖出现率、餐后血糖和胰岛素的曲线下面积;索格列净在5.25小时午餐后仍降低葡萄糖出现率和餐后血糖。索格列净通过延迟和减弱肠道葡萄糖吸收降低餐后血糖和胰岛素,可能源于对肠道SGLT1的持续局部抑制。
要点
- 索格列净降低早餐后葡萄糖出现率、餐后血糖和胰岛素AUC。
- 索格列净在给药后5.25小时午餐仍降低葡萄糖出现率和餐后血糖。
- 索格列净的作用可能与持续抑制肠道SGLT1有关。
核心结论
- 索格列净延迟并减弱餐后肠道葡萄糖吸收,降低餐后血糖和胰岛素水平,可能源于给药后持续≥5小时的肠道SGLT1局部抑制。
研究设计与样本
- 双盲、三周期交叉研究(NCT01916863),24名健康参与者随机分为两个队列各12人。
- 每个队列内参与者随机接受单次口服索格列净400mg、卡格列净300mg或安慰剂,分别在第1、8、15天测试。
- 采用双葡萄糖示踪剂法测量口服葡萄糖出现率(RaO),并检测餐后血糖和胰岛素。
临床怎么用
- 索格列净可能通过延缓肠道葡萄糖吸收控制餐后血糖,支持其双重SGLT1/2抑制机制在临床血糖管理中的应用。
局限性
- 研究仅纳入24名健康参与者,未涉及糖尿病患者。
- 单次给药设计,未评估长期疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The effect of sotagliflozin (a dual sodium-glucose cotransporter [SGLT] 2 and SGLT1 inhibitor) on intestinal glucose absorption has not been investigated in humans. OBJECTIVE: To measure rate of appearance of oral glucose (RaO) using a dual glucose tracer method following standardized mixed meals taken after single sotagliflozin or canagliflozin doses. SETTING: Clinical research organization. DESIGN AND PARTICIPANTS: In a double-blind, 3-period crossover study (NCT01916863), 24 healthy participants were randomized to 2 cohorts of 12 participants. Within each cohort, participants were randomly assigned single oral doses of either sotagliflozin 400 mg, canagliflozin 300 mg, or placebo on each of test days 1, 8, and 15. On test days, Cohort 1 had breakfast containing [6,6-2H2] glucose 0.25 hours postdose and lunch containing [1-2H1] glucose 5.25 hours postdose; Cohort 2 had breakfast containing no labeled glucose 0.25 hours postdose and lunch containing [6,6-2H2] glucose 4.25 hours postdose. All participants received a 10- to 15-hour continuous [U-13C6] glucose infusion starting 5 hours before their first [6,6-2H2] glucose-containing meal. MAIN OUTCOME: RaO, postprandial glucose (PPG), and postprandial insulin. RESULTS: Sotagliflozin and canagliflozin decreased area under the curve (AUC)0-1 hour and/or AUC0-2 hours for RaO, PPG, and insulin after breakfast and/or the 4.25-hour postdose lunch (P < .05 versus placebo). After the 5.25-hour postdose lunch, sotagliflozin lowered RaO AUC0-1 hour and PPG AUC0-5 hours versus both placebo and canagliflozin (P < .05). CONCLUSIONS: Sotagliflozin delayed and blunted intestinal glucose absorption after meals, resulting in lower PPG and insulin levels, likely due to prolonged local inhibition of intestinal SGLT1 that persisted for ≥5 hours after dosing.
引用
- Powell DR, Zambrowicz B, Morrow L, et al. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption. J Clin Endocrinol Metab. 2020. PMID: 31837264. doi:10.1210/clinem/dgz258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。